Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 May 2;14(1):77.
doi: 10.1038/s41408-024-01044-4.

Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison

Mazyar Shadman  1 , Alessandra Tedeschi  2 , Leyla Mohseninejad  3 , Keri Yang  4 , Nicole Lamanna  5 , Sheng Xu  6 , Aileen Cohen  4 , Swetha Challagulla  4 , Mei Xue  4 , Rhys Williams  4 , Susan M O'Brien  7 , Jennifer R Brown  8 , Constantine Tam  9
Affiliations
Comparative Study

Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison

Mazyar Shadman et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

MS reports receiving funding from BeiGene paid to Fred Hutchinson Cancer Research Center and the University of Washington (Seattle, WA, USA), with regards to the submitted work; research funding from Pharmacyclics (Inst), Acerta Pharma (Inst), Merck (Inst), TG Therapeutics (Inst), BeiGene (Inst), Celgene (Inst), Genentech (Inst), MustangBio (Inst), AbbVie (Inst), Sunesis Pharmaceuticals (Inst), Bristol Myers Squibb/Celgene, Genmab (Inst), and Vincerx Pharma (Inst); and consulting or advisory roles with AbbVie, Genentech, AstraZeneca, Sound Biologics, Cellectar, Pharmacyclics, BeiGene, Bristol Myers Squibb/Celgene, MorphoSys, Innate Pharma, Kite, a Gilead Company, Adaptive Biotechnologies, Epizyme, Fate Therapeutics, Lilly, Regeneron, Adaptimmune, MustangBio, TG Therapeutics, and MEI Pharma, outside the submitted work. AT reports receiving consulting fees from AbbVie, AstraZeneca, BeiGene, and Janssen; and honoraria from AbbVie, AstraZeneca, BeiGene, and Janssen, outside the submitted work. LM, KY, SX, AC, SC, MX, and RW are employees of BeiGene, with regards to the submitted work, and report stocks or stock options, or both, from BeiGene, outside the submitted work. NL reports receiving consulting or advisory roles with Celgene, Genentech, AbbVie, ProNAi, Pharmacyclics, Juno Therapeutics, Roche, Janssen, AstraZeneca, Gilead Sciences, BeiGene, and Loxo/Lilly Research; and funding from Genentech/AbbVie (Inst), Infinity Pharmaceuticals (Inst), Gilead Sciences (Inst), ProNAi (Inst), BeiGene (Inst), Verastem (Inst), Juno Therapeutics (Inst), TG Therapeutics (Inst), Acerta Pharma/AstraZeneca (Inst), Loxo (Inst), Oncternal Therapeutics, Inc (Inst), MingSight (Inst), and Octapharm (Inst), outside the submitted work. SMO reports employment with University of California, Irvine; honoraria from Celgene, Janssen, Pharmacyclics, Gilead Sciences, Pfizer, Amgen, Astellas Pharma, GlaxoSmithKline, Aptose Biosciences, Vaniam Group, AbbVie, Sunesis Pharmaceuticals, Alexion Pharmaceuticals, Eisai, TG Therapeutics, and NOVA Research Company; consulting or advisory roles with Amgen, Celgene, GlaxoSmithKline, Janssen Oncology, Aptose Biosciences, Vaniam Group, AbbVie/Genentech, Sunesis Pharmaceuticals, Alexion Pharmaceuticals, Astellas Pharma, Gilead Sciences, Pharmacyclics, TG Therapeutics, Pfizer, and Sunesis Pharmaceuticals; receiving research funding from Acerta Pharma (Inst), Regeneron (Inst), Gilead Sciences (Inst), Pfizer (Inst), TG Therapeutics (Inst), Pharmacyclics (Inst), Kite, a Gilead Company (Inst), Sunesis Pharmaceuticals (Inst), Lilly (Inst), and Caribou Biosciences (Inst); and travel, accommodations, expenses from Celgene, Janssen, Gilead Sciences, Regeneron, and Janssen Oncology. JB reports receiving research funding from BeiGene (Inst), Gilead Sciences (Inst), Loxo/Lilly (Inst), MEI Pharma (Inst), Secura Bio (Inst), Sun Pharma (Inst), and TG Therapeutics (Inst); and consulting or advisory roles with AbbVie, Acerta/AstraZeneca, BeiGene, Bristol Myers Squibb/Celgene/Juno, Catapult Therapeutics, Lilly, Genentech/Roche, HUTCHMED, iOnctura, Janssen, MEI Pharma, MorphoSys, Novartis, and Pharmacyclics, outside of the submitted work. CT reports receiving funding from Janssen-Cilag (Inst), AbbVie (Inst), BeiGene (Inst); consulting or advisory roles with Janssen, Loxo, Roche, BeiGene, and AbbVie; and honoraria from Janssen-Cilag, AbbVie, Novartis, BeiGene, Pharmacyclics, Roche/Genentech, and Loxo/Lilly, outside the submitted work.

Figures

Fig. 1
Fig. 1. Survival outcomes.
A PFS-IRC. B PFS-INV. C OS. aGiven the availability of both IRC- and INV-assessed data. CI confidence interval, CLL chronic lymphocytic leukemia, COVID-19 coronavirus disease-19, EM effect modifier, HR hazard ratio, INV investigator, IPD individual patient-level data, IRC independent review committee, MAIC matching-adjusted indirect comparison, ORR overall response rate, OS overall survival, PF prognostic factor, PFS progression-free survival, RCT randomized clinical trial, R/R relapsed refractory, SLL small lymphocytic lymphoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441–52. doi: 10.1200/JCO.21.01210. - DOI - PMC - PubMed
    1. Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319–32. doi: 10.1056/NEJMoa2211582. - DOI - PubMed
    1. Hillmen P, Eichhorst B, Brown JR, Lamanna N, O’Brien SM, Tam CS, et al. Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial. J Clin Oncol. 2023;41:1035–45. doi: 10.1200/JCO.22.00510. - DOI - PMC - PubMed
    1. Hillmen P, Brown JR, Eichhorst BF, Lamanna N, O’Brien SM, Qui L, et al. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncol. 2020;16:517–23. doi: 10.2217/fon-2019-0844. - DOI - PubMed
    1. Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15:940–7. doi: 10.1016/j.jval.2012.05.004. - DOI - PubMed